SAN FRANCISCO -- Menopause hormone therapy (MHT) was tied to a weight-loss boost in postmenopausal women taking a weight loss ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

Weight loss injections can help people lose more weight than with other methods of weight loss, including lifestyle changes ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

A weight loss drug has been found to dramatically reduce breast cancer tumour growth while still achieving significant weight ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.

Tirzepatide, a new drug that could have far-reaching impact — and billions in sales — is likely to be approved for weight loss by the Food and Drug Administration in 2023.